Tacrolimus for vulvar lichen sclerosus
Topical tacrolimus is the most established alternative to clobetasol when corticosteroids are not the most suitable option. We explain when it is used, how it works, and the evidence supporting it.
Mechanism of action of tacrolimus
Tacrolimus is a calcineurin inhibitor. Unlike corticosteroids, it does not suppress inflammation non-specifically; instead, it acts by specifically blocking the activation of T lymphocytes—the immune system cells involved in the autoimmune response of VLS.
This difference in mechanism has a relevant practical consequence: tacrolimus does not cause skin atrophy. This is precisely why it is particularly useful in situations where the risk of additional atrophy from corticosteroids is a concern—patients with significant pre-existing vulvar atrophy, or in especially delicate anatomical areas.
When tacrolimus is used in VLS
Tacrolimus does not replace clobetasol as first-line treatment—the available evidence is greater for corticosteroids, as established by guidelines. However, it is a valid alternative in specific situations:
> Intolerance or insufficient response to corticosteroids. If corticosteroids produce significant side effects or do not provide the expected control, tacrolimus can be an effective alternative.
> Areas where the use of potent corticosteroids is problematic. The perianal area and certain areas of very thin skin may not tolerate the prolonged use of clobetasol as well.
> Long-term maintenance phase. Some specialists prefer tacrolimus in the maintenance phase due to its better long-term skin safety profile.
What you should know about tacrolimus in VLS
Off-label indication. Tacrolimus has an approved indication for atopic dermatitis, not specifically for VLS. Its use in VLS is a common clinical practice supported by published evidence, but it is outside the official summary of product characteristics. Your specialist should inform you of this.
Black box warning (FDA). In the US, topical tacrolimus carries an FDA warning regarding a possible increased risk of lymphoma and skin cancer with prolonged use. This warning is controversial and is not supported by solid causal evidence, but it should be known. European guidelines (EADV) have a more permissive stance on its long-term use.
Initial burning sensation. A burning or stinging sensation is common during the first applications, which generally decreases with continued use.